Coxiella burnetii is the causative agent of Q fever, a zoonosis occurring worldwide (1). Recently, a large epidemic occurred in the Netherlands with >4,000 cases of acute Q fever notified from 2007 through 2010 (2,3). Chronic Q fever develops in an estimated 1%–5% of all infected humans and can become manifest even years after primary infection (1,4). Endocarditis and infection in aneurysms or vascular protheses are the most common manifestations (1,5,6). Untreated chronic Q fever has a poor prognosis, with a reported mortality rate of up to 60% (1,7). Adequate antibiotic treatment reduces the mortality rate for Q fever endocarditis to <5% (7). Treatment preferably consists of a combination of doxycycline and hydroxychloroquine for at least 18 months (nonprosthetic infection) to 24 months (prosthetic infection) and is recommended to be continued in case of unfavorable clinical or serologic response (7,8). Antibiotic guidelines for vascular chronic Q fever are not yet available, but antibiotic regimes for Q fever endocarditis have been applied to this disease entity as well. Early surgical intervention, with removal of infected material, might improve the prognosis of vascular chronic Q fever (6,9).

In the early course of chronic Q fever, most patients are asymptomatic or experience nonspecific symptoms such as low-grade fever, night sweats, and weight loss (1,4,6,7). In the case of endocarditis, findings on echocardiograph are often nonspecific or absent, which makes the diagnosis of chronic Q fever challenging (7). A PCR positive for C. burnetii or culture of the organism in blood or tissue, in the absence of acute Q fever, is a strong indicator for chronic Q fever. However, sensitivity on blood samples is only 50%–60% for both PCR and culture in patients with chronic Q fever (10,11). Therefore, serologic testing is also valuable for the diagnosis of chronic Q fever. A phase I IgG cutoff titer of 1:800, which is based on an in-house–developed immunofluorescence assay (IFA), has been internationally accepted for the diagnosis of chronic Q fever and is included in the modified Duke criteria for diagnosis of endocarditis (12,13). In the Netherlands, a commercial IFA (Focus Diagnostics, Inc., Cypress, CA, USA) is primarily used, with a proposed IgG cutoff value of 1:1,024 for chronic Q fever (14). Yet, recent studies show that serology results alone are not sufficient for the diagnosis of chronic Q fever, but that they should be combined with clinical data (15).

A complete list of the group members is provided at the end of this article.

DOI: http://dx.doi.org/10.3201/eid2107.130955
**Dutch Consensus Guideline**

Faced with a large Q fever outbreak in the Netherlands and a rising number of (presumed) chronic Q fever patients, we were not able to find answers to all our questions about this complex disease in the literature. Moreover, randomized trials on diagnosis and treatment of this disease were lacking, and available data were not all applicable to the Dutch situation. For example, we found far more vascular localizations of chronic Q fever, with often severe complications, than had been described previously. Therefore, the Dutch Q Fever Consensus Group was initiated in 2010, in which diagnosis and subsequent treatment consequences for suspected chronic Q fever were discussed. We performed a thorough literature review and constructed a new guideline for the diagnosis of chronic Q fever, differentiating between proven, probable, and possible chronic Q fever (Table 1). We added advice for treatment and follow-up regimes for these 3 groups of patients. Antibiotic treatment and, if indicated, surgical treatment are recommended for all patients with proven chronic Q fever. The decision to start antibiotic treatment in patients with probable chronic Q fever depends on clinical characteristics and the condition of the patient, and should be determined by a multidisciplinary team. For possible chronic Q fever patients, antibiotic treatment should not be initiated, but follow-up is indicated.

After the Dutch consensus guideline was reported (14), a reaction by French researcher Didier Raoult was published; he did not agree with this proposed guideline and formulated alternative diagnostic criteria on the basis of his expert opinion (Table 2) (16). Professor Raoult is the undisputed leading authority on Q fever, and his opinion and the scientific publications from his research group should be considered by anyone working in the field of Q fever. Here, we attempt to resolve these differences of opinion by applying both criteria to cases from the Dutch National Chronic Q Fever Database.

**Dutch Consensus Guideline versus Expert Opinion Guideline**

A critical difference in the diagnostic criteria proposed by Raoult and those of the Dutch Q Fever Consensus Group is the diagnostic value attributed to *C. burnetii* PCR positivity of blood samples. Because we are unaware of clinical entities, other than acute and chronic Q fever, for which a PCR positive for *C. burnetii* in blood would be exhibited, we believe that positive blood PCR findings, in the absence of acute Q fever, prove chronic Q fever. The alternative criteria, on the other hand, state that a positive PCR finding in blood should be accompanied by a clear endocarditis focus shown on echocardiograph, a clear vascular focus on imaging studies, or at least 2 or 3 “minor criteria” (Table 2). Moreover, the alternative criteria attribute great value to the phase I IgG titer, proposing a phase I IgG ≥1:6,400 as a major criterion for Q fever endocarditis and Q fever vascular infection, in contrast to a phase I IgG ≥1:800 and <1:6,400 proposed as a minor criterion. This proposal contradicts the internationally accepted modified Duke criteria, which state that a phase I IgG ≥1:800 is a major criterion for infective (Q fever) endocarditis (13).

The alternative criteria also generally oppose the term chronic Q fever but makes a distinction in 2 manifestations: Q fever endocarditis and Q fever vascular infection. More

### Table 1. Dutch consensus guideline on chronic Q fever diagnostics*

<table>
<thead>
<tr>
<th>Proven chronic Q fever</th>
<th>Probable chronic Q fever</th>
<th>Possible chronic Q fever</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Positive <em>Coxiella burnetii</em> PCR of blood or tissue†</td>
<td>IFA ≥1:1,024 for <em>C. burnetii</em> phase I IgG‡</td>
<td>IFA ≥1:1,024 for <em>C. burnetii</em> phase I IgG‡ without manifestations meeting the criteria for proven or probable chronic Q fever</td>
</tr>
<tr>
<td>OR 2. IFA ≥1:800 or 1:1,024 for <em>C. burnetii</em> phase I IgG‡ AND Definite endocarditis according to the modified Duke criteria (13) OR Proven large vessel or prosthetic infection by imaging studies (FDG-PET, CT, MRI, or AUS)</td>
<td>Valvulopathy not meeting the major criteria of the modified Duke criteria (13) Known aneurysm and/or vascular or cardiac valve prosthesis without signs of infection by means of TEE/ TTE, FDG-PET, CT, MRI, or AUS Suspected osteomyelitis or hepatitis as manifestation of chronic Q fever Pregnancy Symptoms and signs of chronic infection, such as fever, weight loss and night sweats, hepato-splenomegaly, persistent raised ESR and CRP Granulomatous tissue inflammation, proven by histological examination Immunocompromised state</td>
<td></td>
</tr>
</tbody>
</table>

*Source: (14). IFA, immunofluorescence assay; TEE, transesophageal echocardiography; TTE, transthoracic echocardiography; FDG-PET, fluorodeoxyglucose positron emission tomography; CT, computed tomography; MRI, magnetic resonance imaging; AUS, abdominal ultrasound; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
†In the absence of acute infection.
‡Cut-off depends on the IFA technique used, whether in-house developed or commercial.
Table 2. Diagnostic guideline for chronic Q fever proposed by Raoult*

Q fever endocarditis

<table>
<thead>
<tr>
<th>A. Definite criteria</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive culture, PCR, or immunochemistry of a cardiac valve</td>
<td></td>
</tr>
<tr>
<td>Microbiology: positive culture or PCR of the blood or an emboli or serology with IgG I antibodies ≥6,400</td>
<td></td>
</tr>
<tr>
<td>Evidence of endocardial involvement: Echocardiogram positive for IE: oscillating intra-cardiac mass on valve or supporting structure, in the path of regurgitant jets, or on implanted material in the absence of an alternative anatomic explanation; or abscess; or new partial dehiscence of prosthetic valve; or new valvular regurgitation (worsening or changing of pre-existent murmur not sufficient)</td>
<td></td>
</tr>
<tr>
<td>PET scan showing a specific valve fixation and mycotic aneurysm</td>
<td></td>
</tr>
</tbody>
</table>

B. Major criteria

C. Minor criteria

Diagnosis possible

1. 1B, 2C criterion (including microbiology evidence, and cardiac predisposition)

Diagnosis definite

1. 1B criterion, 2C criteria (including microbiology evidence, and cardiac predisposition)

2. 3C criterion (including positive serology, and cardiac predisposition)

Diagnosis possible

1. 1B criterion, 2C criteria (including microbiology evidence, and cardiac predisposition)

2. 3C criterion (including positive serology, and cardiac predisposition)

Q fever vascular infection

A. Definite criteria

Positive culture, PCR, or immunochemistry of an arterial sample (prosthesis or aneurysm) or a periarterial abscess or a spondylodiscitis linked to aorta

B. Major criteria

Microbiology: positive culture or PCR of the blood or an emboli or serology with IgG I antibodies ≥6,400

Evidence of vascular involvement: CT scan: aneurysm or vascular prosthesis + p PET scan: specific fixation on an aneurysm or vascular prosthesis

C. Minor criteria

Serological IgG I ≥800 <6,400

Fever, temperature >38°C

Emboli

Underlying vascular predisposition (aneurysm or vascular prosthesis)

Diagnosis definite

1. 1A criterion

2. 2B criterion

3. 1B and 2C criterion (including microbiology findings and vascular predisposition)

Diagnosis possible

Vascular predisposition, serological evidence and fever or emboli

*Source: (16). IE, infective endocarditis; PET, positron emission tomography; IFA, immunofluorescence assay; CT, computed tomography.

Chronic Q Fever Diagnosis

rare manifestations, such as pericarditis, hepatitis, and osteomyelitis, are left undefined, however.

After the recent outbreak of Q fever in the Netherlands, we initiated the Dutch National Chronic Q Fever Database, a joint effort by multiple hospitals in areas affected by Q fever, to monitor all chronic Q fever cases in the Netherlands. All hospitals with chronic Q fever patients, also outside the notified Q fever–epidemic areas, were actively approached. Design of the database and use of the collected information for analysis and scientific publications were approved by the Medical Research Ethics Committee of the University Medical Center Utrecht in Utrecht, the Netherlands. Part of these data had previously been published in a report discussing serologic profiles of patients with chronic Q fever (15).

Until the end of May 2012, a total of 284 patients had been included in our database (although the epidemic started in 2009, all patients from 2006 on are included): 151 patients (53.2%) had proven chronic Q fever, 64 patients (22.5%) had probable chronic Q fever, and 69 patients (24.3%) had possible chronic Q fever, according to the Dutch consensus guideline. We reevaluated these chronic Q fever cases with the alternative diagnostic criteria (Table 3). Of the case-patients with proven chronic Q fever according to the Dutch guideline, 46 (30.5%) would have been left undiagnosed with the alternative criteria. For cases of probable chronic Q fever, 58 cases (90.6%) would have been undiagnosed, and for possible cases of chronic Q fever, 69 cases.

The conditions of 8 patients with proven chronic Q fever (based on PCR positivity for C. burnetii in blood and suspicion of endocarditis) would have been diagnosed with possible Q fever endocarditis only by the alternative criteria (Table 4). Eighteen patients with proven chronic Q fever would not have been diagnosed with Q fever endocarditis at all, because echocardiography results did not match any major clinical Duke criterion, as is often observed in cases of Q fever endocarditis (7). Of the 8 patients with proven chronic Q fever endocarditis (by Dutch consensus guideline) who had been given a diagnosis of possible endocarditis according to the alternative criteria, 2 patients would have been considered to have definite endocarditis by the modified Duke criteria (13). Seventeen of these patients had a positive vascular lesion on fluorodeoxyglucose–positron emission tomography/computed tomography (FDG-PET/CT) with phase 1 IgG ≥1:800 and <1:6,400. Seven patients had a PCR of blood positive for C. burnetii, in combination with an aneurysm or vascular prosthesis but no signs of infection on FDG-PET/CT. According to the Dutch consensus
Table 3. Comparison of chronic Q fever diagnosis according to the Dutch consensus guideline* and the alternative criteria†

<table>
<thead>
<tr>
<th>Alternative criteria</th>
<th>Dutch consensus chronic Q fever guideline</th>
<th>Proven, no. (%), n = 151</th>
<th>Probable, no. (%), n = 64</th>
<th>Possible, no. (%), n = 69</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definite Q fever endocarditis</td>
<td></td>
<td>21 (13.9)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Possible Q fever endocarditis</td>
<td></td>
<td>8 (5.3)</td>
<td>4 (6.3)</td>
<td>0</td>
</tr>
<tr>
<td>Definite Q fever vascular infection</td>
<td></td>
<td>76 (50.3)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Possible Q fever vascular infection</td>
<td></td>
<td>0</td>
<td>2 (3.1)</td>
<td>0</td>
</tr>
<tr>
<td>No diagnosis of chronic Q fever</td>
<td></td>
<td>46 (30.5)</td>
<td>58 (90.6)</td>
<td>69 (100.0)</td>
</tr>
</tbody>
</table>

*Source: (14).
†Source: (16).

Table 4. Characteristics and outcome of patients diagnosed with chronic Q fever using the Dutch consensus guideline* but without (definite) chronic Q fever according to alternative criteria†

<table>
<thead>
<tr>
<th>Dutch consensus guideline</th>
<th>Alternative criteria</th>
<th>Possible Q fever endocarditis or vascular infection, no. (%), n = 14</th>
<th>No diagnosis, no. (%), n = 173</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proven Q fever</td>
<td>Endocarditis</td>
<td>8 (57.1)</td>
<td>46 (26.8)</td>
</tr>
<tr>
<td></td>
<td>PCR positive for Coxiella burnetii in blood</td>
<td>8 (57.1)</td>
<td>18 (10.4)</td>
</tr>
<tr>
<td></td>
<td>Evidence of endocardial involvement</td>
<td>6 (42.9)</td>
<td>18 (10.4)</td>
</tr>
<tr>
<td></td>
<td>Vascular infection</td>
<td>2 (14.3)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>PCR positive in blood</td>
<td>0</td>
<td>24 (13.9)†</td>
</tr>
<tr>
<td></td>
<td>Vascular focus on imaging</td>
<td>0</td>
<td>7 (4.0)</td>
</tr>
<tr>
<td></td>
<td>Other or no focus§</td>
<td>0</td>
<td>17 (9.8)</td>
</tr>
<tr>
<td></td>
<td>Deceased</td>
<td>2 (14.3)</td>
<td>8 (4.6)</td>
</tr>
<tr>
<td></td>
<td>Death probably due to Q fever</td>
<td>2 (14.3)</td>
<td>4 (2.3)†</td>
</tr>
<tr>
<td>Probable Q fever</td>
<td>Endocarditis</td>
<td>6 (42.9)</td>
<td>58 (33.5)</td>
</tr>
<tr>
<td></td>
<td>Vascular infection</td>
<td>4 (28.6)</td>
<td>22 (12.7)</td>
</tr>
<tr>
<td></td>
<td>Other or no focus§</td>
<td>2 (14.3)</td>
<td>16 (9.3)</td>
</tr>
<tr>
<td></td>
<td>Deceased</td>
<td>0</td>
<td>20 (11.6)</td>
</tr>
<tr>
<td></td>
<td>Death probably due to Q fever</td>
<td>2 (14.3)</td>
<td>4 (2.3)</td>
</tr>
<tr>
<td></td>
<td>Possible Q fever</td>
<td>1 (7.1)</td>
<td>0</td>
</tr>
</tbody>
</table>

*Source: (14).
†Source: (16).
‡In 3 patients with proven chronic Q fever, imaging studies showed that the focus of infection was in both the heart valves and the vascular structures.
§All were PCR positive.
¶For 2 patients, PCR of vascular and heart valve tissue obtained at autopsy was positive for C. burnetii.

Conclusions

Several major differences exist between the Dutch consensus guideline for the diagnosis of chronic Q fever and the alternative criteria. These alternative criteria define only Q fever endocarditis and Q fever vascular infection and oppose the term chronic Q fever. However, this distinction
is not accompanied by therapeutic consequences for each of these manifestations, which we believe makes these guidelines less practical.

It must be acknowledged that, because all patients included in our study met the Dutch criteria for proven, probable, or possible chronic Q fever, other guidelines can only perform with less accuracy in comparison. Nevertheless, sensitivity of the Dutch guideline is markedly higher than with the alternative criteria: ≈31% of proven chronic Q fever case-patients would have been missed as well as almost all patients with probable and possible cases, including at least 4 patients who eventually died of chronic Q fever related causes. Specificity of the Dutch consensus guideline is probably lower than that of the alternative criteria, but because mortality and morbidity rates are high when chronic Q fever cases are untreated, we believe sensitivity is of greater importance in clinical practice. Our data illustrate that, when proven cases of chronic Q fever are missed, and patients are therefore not adequately treated, these patients are at high risk for severe complications and death.

As stated before, the most critical difference between the criteria of the Dutch guideline and those of the alternative guideline is the acknowledgment of a positive C. burnetii PCR as a marker of proven chronic Q fever in the absence of acute Q fever. Of course, this difference should be interpreted with care. In our opinion, patients without endocarditis or vascular infection on imaging studies but with a positive PCR in blood should also be treated for chronic Q fever, as they may suffer from not yet clinically visible endocarditis or vascular infection, which was confirmed by the postmortem results of 2 of our patients described above. A single positive C. burnetii PCR of blood is highly suggestive for chronic Q fever when acute Q fever is excluded. A PCR test will not be performed in patients without symptoms and without any risk factors for chronic Q fever, so cases in whom a positive PCR is the only factor indicating chronic Q fever is a theoretical consideration. We have observed few patients, in the absence of signs of acute Q fever, with elevated phase I IgG titers not fulfilling the serologic criteria of chronic Q fever (phase I IgG ≥1:800 or 1,024) but with a positive C. burnetii PCR of blood or tissue. In these cases, we are convinced that PCR-positivity proves chronic Q fever. No patients in our chronic Q fever database who had a positive PCR on blood should also be treated for chronic Q fever manifestations that are rarer than endocarditis and vascular infection.

We hope that, with the future results from the Dutch National Chronic Q Fever Database and joint efforts of international researchers and experts in the field of Q fever, these guidelines can be modified to provide definite evidence-based criteria for diagnosis and treatment of this complex disease. In the meantime, the Dutch consensus guideline created on the basis of the scarce available literature is, in our opinion, safer and easier to use in clinical practice than the alternative expert-based criteria.

Acknowledgments
We thank all participants in the Dutch National Chronic Q Fever Database in the Netherlands: Monique de Jager-Leclercq (Bernhoven Hospital, Oss), Cornelis A.R. Groot (Bernhoven Hospital), Yvonne Soethoudt (Elkerliek Hospital, Helmond), Sybrandus N. Blank (Maxima Medical Center, Eindhoven/Veldhoven), Marijolijn J.H. Pronk (Catharina Hospital, Eindhoven), Gis J. Limonard (Diaconessenhuis, Utrecht), Steven F. Thijssen (Diaconessenhuis), Bart J. Vlaminckx (St Antonius Hospital, Nieuwegein), Jacqueline Buijs (Atrium Medical Center, Heerlen), Bas J.M van Kraaij (Atrium Medical Center), Frederika Dijkstra (Centre for Infectious Disease Control, Bilthoven), Clemens Richter (Rijnstate Hospital, Arnhem), E.H. Gisolf (Rijnstate Hospital, Arnhem), Rik Heijligenberg (Gelderse Vallei Hospital, Ede), Ries Schouten (Gelderse Vallei Hospital), Karin Schurink (Erasmus University Medical Center, Rotterdam), Leo G. Visser (Leiden University Medical Center, Leiden).

Dr. Kampschreur is a physician and PhD researcher in the Division of Medicine, Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht. Her recent research focuses on chronic Q fever in the Netherlands.

References


Address for correspondence: Linda M. Kampschreur, Division of Medicine, Department of Internal Medicine and Infectious Diseases, Room F02-107, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, the Netherlands; email: lindakampschreur@hotmail.com

---

**November 2014: Foodborne Infections**

**Including:**

- Blastomycosis Mortality Rates, United States, 1990–2010
- Death Patterns during the 1918 Influenza Pandemic in Chile
- Genomic Definition of Hypervirulent and Multidrug-Resistant *Klebsiella pneumoniae* Clonal Groups
- Respiratory Viruses and Bacteria among Pilgrims during the 2013 Hajj
- Drug-Resistant *Candida glabrata* Infection in Cancer Patients
- Novel *Chlamydia trachomatis* Strains in Heterosexual Sex Partners, Indianapolis, Indiana, USA